PP  Vol.4 No.9 , December 2013
Tenofovir Renal Toxicity: Evaluation of Cohorts and Clinical Studies—Part One
Abstract: Tenofovir is one of the most commonly used antiretrovirals in adolescents and adults because of its potency and favorable pharmacokinetic and relative safety toxicological profile. It has been combined successfully with antiretroviral drugs from classes such as protease inhibitors, non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors to achieve virologic suppression in a high percentage of recipients. Despite its therapeutic success, quite a number of cohorts and clinical studies have associated tenofovir with the development of renal toxicity with few studies on the opposing end. This stimulated us to review reported cohorts and clinical studies on tenofovir renal toxicity. In this study it was observed that literature reported incidence of tenofovir renal toxicity falls within the range of 0.7%-17%. Available studies gave different appellations to tenofovir renaltoxicity, which include fanconis syndrome, proximal tubule dysfunction, acute renal failure, chronic renal failure, chronic kidney disease and nephrogenic diabetes insipidus. Markers of renal toxicity (tubulopathy) which include glycosuria, hyperaminoaciduria, proteinuria, hyperphosphaturia, hyperuricosuria, retinol-binding protein, beta2-microglobulinuria, decreased creatinine clearance and decreased glomerular filtration rate were also reported. In some studies renal biopsy demonstrated cytoplasmic vacuolization, apical localization of nuclei and reduction of the brush border on proximal tubule epithelial cells. This study observed that tenofovir renal toxicity could be reversible on discontinuation of tenofovir therapy despite contrary views by some studies. Regardless of tenofovir reported renal toxicity, it is well tolerated with a relative safety profile but it is advised that renal profile of patients should be evaluated before and routinely during tenofovir therapy.
Cite this paper: A. Elias, O. Ijeoma, N. Edikpo, D. Oputiri and O. Geoffrey, "Tenofovir Renal Toxicity: Evaluation of Cohorts and Clinical Studies—Part One," Pharmacology & Pharmacy, Vol. 4 No. 9, 2013, pp. 651-662. doi: 10.4236/pp.2013.49092.

[1]   L. R. Smith, R. de Boer, S. Brul, Y. Budovskaya and H. Van der Spek, “Premature and Accelerated Aging: HIVor HAART?” Frontiersin Genetics|Genetics of Aging, Vol. 3, No. 328, 2013. pp. 1-10.

[2]   M. Dybul, A. S. Fauci, J. G. Bartlett, J. E. Kaplan and A. K. Pau, “Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents,” Annals of Internal Medicine. Vol. 137, No. 5, 2002, PP, 381–433.

[3]   J. L. Ngondi, J. Oben, D. M. Forkah, L. H. Etame and D. M. Banya, “The Effect of Different Combination Therapies on Oxidative Stress Markers in HIV Infected Patients in Cameroon,” AIDS Research and Therapy, Vol. 3, No. 19, 2006, pp. 1-7.

[4]   A. Elias and N. Brambaifa, “Concentration-Effect, Incidence and Mechanism of Nevirapine Hepatotoxicity,” American. Journal of Pharmacology and Toxicology, Vol. 8, No. 1, 2013, pp. 20-30.

[5]   A. Elias, D. Oputiri, O. P. Geoffrey and D. A. Enimeya, “Nevirapine Hepatotoxicity Implication of Risk Factors,” American Journal of Pharmacology and Toxicology, Vol. 8, No. 2, 2013, pp. 51-63.

[6]   A. Mandas, E. L. Iorio, M. G. Congiu, C. Balestrieri, A. Mereu, et al., “Oxidative Imbalance in HIV-1 Infected Patients Treated with Antiretroviral Therapy,” Journal of Biomedicine and Biotechnology, 2009, Article ID: 749575.

[7]   S. Mouss, F. Berger and G. Schmutz, “Antiretroviral Therapy with Tenofovir Is Associated with Mild Renal Dysfunction,” AIDS, Vol. 19, No. 1, 2005, pp. 93-99.

[8]   K. A. Lyseng-Williamson, N. A. Reynolds and G. L. Plosker, “Tenofovir Disoproxil Fumarate: A Review of Its Use in the Management of HIV Infection,” Drugs, Vol. 65, No. 3, 2005. pp. 413-432.

[9]   T. M. Chapman, J. K. McGavin and S. Noble, “Tenofovir Disoproxil Fumarate,” Drugs, Vol. 63, No. 15, 2003, pp. 1597-1608.

[10]   J. M. Lucey, P. Hsu and J. B. Ziegler, “Tenofovir Related Fanconis Syndrome and Osteomalacia in a Teenager with HIV,” British Medical Journal Case Report, 2013

[11]   WHO, “Antiretroviral Therapy for HIV Infection in Adolescents and Adults: Recommendations for a Public Health Approach,” World Health Organization, Geneva, 2010.

[12]   R. V. Srinivas and A. Fridland, “Antiviral Activities of 9-R-2-Phosphonomethoxypropyl Adenine (PMPA) and Bis(isopropyloxymethylcarbonyl) PMPA against Various Drug-Resistant Human Immunodeficiency Virus Strains,” Antimicrobial Agents Chemotherapy, Vol. 42, No. 6, 1998, pp. 1484-1487.

[13]   B. L. Robbins, R. V. Srinivas, C. Kim, N. Bischofberger and A. Fridland, “Anti-Human Immunodeficiency virus Activity and Cellular Metabolism of a Potential Prodrug of the Acyclic Nucleoside Phosphonate 9-R-(2-Phosphonomethoxypropyl)adenine (PMPA), Is (isopropyloxymethylcarbonyl) PMPA,” Antimicrobial Agents Chemotherapy, Vol. 42, 1998, pp. 612-617.

[14]   B. P. Kearney, J. F. Flaherty and J. Shah, “Tenofovir Disoproxil Fumarate: Clinical Pharmacology and Pharmacokinetics,” Clinical Pharmacokinetics, Vol. 43, No. 9, 2004, pp. 595-612.

[15]   J. P. Shaw, C. M. Sueoko, R. Oliyai, W. A. Lee, et al., “Metabolism and Pharmacokinetics of Novel Oral Prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in Dogs,” Pharmarmacological Research, Vol. 14, No. 12, 1997, pp. 1824-1829.

[16]   A. M. James, I. Ofotokun, A. Sheth, P. Edward, A. costa, R. Jennifer and R. King, “Tenofovir: Once-Daily Dosage in the Management of HIV Infection,” Clinical Medicine Insights: Therapeutics, Vol. 4, 2012, pp. 201-216.

[17]   P. Barditch-Crovo, S. G. Deeks, A. Collier, S. Safrin, et al., “Phase i/ii Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus Infected Adults,” Antimicrobial Agents Chemotherapy, Vol. 45, No. 10, 2001, pp. 2733-2739.

[18]   HIV/AIDS Treatment Guidelines/AIDSinfo.

[19]   H. J. Stellbrink, C. Orkin, J. R. Arribas, J. Compston and J. Gerstoftetal, “Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study,” Clinical Infectious Diseases, Vol. 51, No. 8, 2010, pp. 963-972.

[20]   M. D. Murphy, M. O’Hearn and M. S. Chou, “Fatal Lactic Acidosis and Acute Renal Failure after Addition of Tenofovir to an Antiretroviral Regimen Containing Didanosine,” Clinical Infectious Diseases, Vol. 36, No. 8, pp. 1082-1085.

[21]   G. Mathew and S. J. Knaus, “Acquired Fanconi’s Syndrome Associated with Tenofovir Therapy,” Journal of Green Internal Medicine, Vol. 21, No. 11, 2006, pp. 3-5.

[22]   Gilead, “Product Monograph Tenofovir Disoproxil Fumarate Tablets 300 mg,” CA2012, Gilead Sciences, Inc., Foster City, 2012.

[23]   M. M. Rosenvinge, K. Gedela, A. J. Copas, A. Wikinson et al., “Tenofovir-Linked Hyperparathyroidism Is Independently Associated with the Presence of Vitamin D Deficiency,” Journal of Acquired Immune Deficiency Syndromes, Vol. 54, No. 5, 2010, pp. 496-499.

[24]   K. E. Childs, S. L. Fisherman, C. Constable, J. A. Gutierrez, et al., “Short Communication: Inadequate Vitamin D Exacerbates Parathyroid Hormone Elevations in Tenofovir Users,” AIDS Research and Human Retroviruses, Vol. 26, No. 8, 2010, pp. 855-859.

[25]   B. Kearney, J. Flaherty and J. Sayre, “A Multiple-Dose Randomized, Crossover Drug Interaction Study between Tenofovir DF and Lamivudine or Didanosine,” The 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, 8-11 July 2001.

[26]   A. S. Mulato and J. M. Cherrington, “Anti-HIV Activity of Adefovir (PMEA) and PMPA in Combination with Antiretroviral Compounds: In Vitro Analyses,” Antiviral Research, Vol. 36, No. 2, 1997, pp. 91-97.

[27]   D. Miller, “K65R TAMs and Tenofovir,” AIDS Review, Vol. 6, No. 1, 2002, pp. 22-23.

[28]   L. Gardner, R. Klein, L. A. Szczech, et al., “HIV Epidemiology Research Study Group Rates and Risk Factors For Condition-Specific Hospitalizations in HIV-Infected and Uninfected Women,” Journal of Acquired Immune Deficiency Syndrome, Vol. 34, No. 3, 2003, pp. 320-330.

[29]   L. A. Szczech, D. R. Hoover, J. G. Feldman, et al., “Association between Renal Disease and Outcomes among HIV-Infected Women Receiving or Not Receiving Antiretroviral Therapy,” Clinical Infectious Disease, Vol. 39, No. 8, 2004, pp. 1199-1206.

[30]   T. K. S. Rao, E. A. Friedman and D. Nicastri, “The Types of Renal Disease in the Acquired Immunodeficiency Syndrome,” New England Journal of Medicine, Vol. 316, No. 2, 1987, pp. 1062-1068.

[31]   S. Naicker, T. M. Han and J. Fabian, “HIV/AIDS— Dominant Player in Chronic Kidney Disease,” Ethnicity & Disease, Vol. 16, No. 2, 2006, pp. 56-60.

[32]   R. J. Glassock, A. H. Cohen, G. Danovitch and K. P. Parsa, “Human Immunodeficiency Virus and the Kidney,” Annals of Internal Medicine, Vol. 112, No. 6, 1990, pp. 35-49.

[33]   R. M. Selik, R. H. Byers and M. S. Dworkin, “Trends in Diseases Reported on US Death Certificates that Mentioned HIV Infection, 1987-1999,” Journal of Acquired Immune Deficiency Syndrome, Vol. 29, No. 4, 2002, pp. 378-387.

[34]   V. Shahinian, S. Rajaraman, M. Borucki, J. Grady, M. Hollander and T. Ahuja, “Prevalence of HIV-Associated Nephropathy in Autopsies of HIV-Infected Patients,” American Journal of Kidney Disease, Vol. 35, No. 5, 2000, pp. 884-888.

[35]   L. A. Szczech, S. J. Gange, C. Van der Horst, et al., “Predictors of Proteinuria and Renal Failure among Women with HIV Infection,” Kidney International, Vol. 61, No. 1, 2002, pp. 195-202.

[36]   E. Deti, R. Thiebaut, F. Bonnet, et al., “Prevalence and Factors Associated with Renal Impairment in HIV-Infected Patients, ANRS C03 Aquitaine Cohort, France,” HIV Medicine, Vol. 11, No. 5, 2010, pp. 308-317.

[37]   N. Franceschini, S. Napravnik, J. Eron, L. A. Szczech and W. F. Finn, “Incidence and Etiology of Acute Renal Failure among Ambulatory HIV Infected Patients,” Kidney International, Vol. 67, 2005, pp. 1526-1531.

[38]   US Renal Data System (USRDS), “USRDS 2001 Annual Data Report,” Bethesda MD, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001.

[39]   L. A. Szczech, S. K. Gupta, R. Habash, A. Guasch, R. Kalayjian, et al., “The Clinical Epidemiology and Course of the Spectrum of Renal Diseases Associated with HIV infection,” Kidney International, Vol. 66, No. 3, 2004, pp. 1145-1152.

[40]   A. I. Choi, R. A. Rodriguez, P. Bacchetti, et al., “Racial Differences in End-Stage Renal Disease Rates in HIV Infection versus Diabetes,” Journal of American Society of Nephrology, Vol. 18, No. 11, 2007. pp. 2968-2974.

[41]   G. Lucas, B. Lau, M. Atta, D. Fine, J. Keruly and R. Moore, “Chronic Kidney Disease Incidence and Progression to End-Stage Renal Disease, in HIV-Infected Individuals: A Tale of Two Races,” Journal of Infectious Disease, Vol. 197, No. 11, 2008, pp. 1548-1557.

[42]   S. Hailemariam, M. Walder, H. R. Burger, G. Cathomas, et al., “Renal Pathology and Premortem Clinical Presentation of Caucasian Patients with AIDS: An Autopsy Study from the Era Prior to Antiretroviral Therapy,” Swiss Medical Weekly, Vol. 131, No. 27-28, 2001, pp. 412-417.

[43]   J. Fabian and S. Naicker, “HIV and Kidney Disease in Sub-Saharan Africa,” Nature Reviews Nephrology, Vol. 5, 2009, pp. 591-598.

[44]   S. Fernando, F. Finkelstein, B. Moore and S. Weissman, “Prevalence of Chronic Kidney Disease in an Urban HIV Infected Population,” American Journal of Medical Science, Vol. 335, No. 2, 2008, pp. 89-94.

[45]   G. M. Lucas, J. A. Eustace, S. Sozio, E. K. Mentari, K. A. Appiah and R. D. Moore, “Highly Active Antiretroviral Therapy and the Incidence of HIV-1-Associated Nephropathy: A 12-Year Cohort Study,” AIDS, Vol. 18, No. 3, 2004, pp. 541-546.

[46]   C. M. Wyatt, J. A. Winston, C. D. Malvestutto, et al., “Chronic Kidney Disease in HIV Infection: An Urban Epidemic,” AIDS, Vol. 21, No. 5, 2007, pp. 2101-2103.

[47]   J. Roling, H. Schmid, M. Fischereder, R. Draenert and F. D. Goebel, “HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy—Induced Nephropathy,” Clinical Infectious Diseases, Vol. 42, No. 10, 2006, pp. 1488-1495.

[48]   S. K. Gupta, “Tenofovir-Associated Fanconi Syndrome: Review of the FDA Adverse Event Reporting System,” AIDS Patient Care and STDs, Vol. 22, No. 2, 2008, pp. 99-103.

[49]   F. Zoulim, S. Radenne and C. Ducerf, “Management of Patients with Decompensated Hepatitis B Virus Association Cirrhosis,” Liver Transplantation, Vol. 14, No. 2, 2008, pp. 1-7.

[50]   P. Bonfanti, G. V. De Socio, S. Carradori et al., “Tenofovir Renal Safety in HIV-Infected Patients: Results from the SCOLTA Project,” Biomedicine and Pharmacotherapy,” Vol. 62, No. 1, 2008, pp. 6-11.

[51]   T. Antoniou, J. Raboud, S. Chirhin, D. Yoong. V. Govan, et al., “Incidence of and Risk Factors for Tenofovir-Induced Nephrotoxicity: A Retrospective Cohort Study,” HIV Medicine, Vol. 6, No. 4, 2005, pp. 284-290.

[52]   S. Pujari, A. Dravid, N. Gupta, K. Joshix and V. Bele, “Effectiveness and Safety of Generic Fixed Dose Combination of Tenofovir/Emtricitabine/Efavirenz in HIV-1 Infected Patients in Western India,” Journal of International Aids Society, Vol. 10, No. 196, 2008, pp. 2-6.

[53]   B. R. Buchacz, K. Young, K. Baker, et al., “Renal Function in Patients Receiving Tenofovir with Ritonavir/Lopinavir or Ritonavir/Atazanavir in the HIV Outpatient Study (HOPS) Cohort,” Journal of Acquired Immune Deficiency Syndromes, Vol. 43, No. 5, 2006, pp. 626-628.

[54]   A. Brennan, D. Evans, M. Maskew, S. Naicker and P. Ive, “Relationship between Renal Dysfunction, Nephrotoxicity and Death among HIV Adults on Tenofovir,” AIDS, Vol. 25, No. 13, 2011, pp. 1603-1609.

[55]   M. Harris, B. Yip, N. Zalunardo, et al., “Increases in Creatinine during Therapy with Tenofovir,” 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, 2003, Abstract 55.

[56]   R. Scherzera, M. Estrellab, Y. Lia, S. G. Deeksc, C. Grunfelda and M. G. Shlipaka, “Association of Tenofovir Exposure with Kidney Disease Risk in HIV Infection,” AIDS, Vol. 26, No. 7, 2012, pp. 1-9.

[57]   R. Jones, J. Stebbing, M. Nelson, et al., “Renal Dysfunction with Tenofovir Disoproxil Fumarate-Containing Highly Active Antiretroviral Therapy Regimens Is Not Observed More Frequently: A Cohort and Case-Control Study,” Journal of Acquired Immune Deficiency Syndrome, Vol. 37, No. 4, 2004, pp. 1489-1495.

[58]   R. D. Cooper, N. Wiebe, N. Smith, P. Keiser, S. Naicker and M. Tonelli, “Systematic Review and Meta-Analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIVInfected Patients,” Clinical Infectious Diseases, Vol. 51, No. 5, 2010, pp. 496-505.

[59]   S. Padilla, F. Gutierrez, M. Masia, V. Canovas and C. Orozco, “Low Frequency of Renal Function Impairment During One-Year of Therapy with Tenofovir-Containing Regimens in the Realworld: A Case-Control Study,” AIDS Patient Care STDS, Vol. 19, No. 7, 2005, pp. 421-424.

[60]   A. Gupta, A. Bugeja and D. Kirpalani, “Tenofovir Induce Nephrotoxicity Myth and Fact,” Saudi Journal of Kidney Disease and Transplantation, Vol. 23. No. 1, 2012, pp. 148-149.

[61]   D. Verhelst, M. Monge, J. L. Meynard , B. Fouqueray, B. Mougenot, et al., “Fanconi Syndrome and Renal Failure induced by Tenofovir: A First Case Report,” American Journal of Kidney Disease, Vol. 40, No. 6, 2002, pp. 1331-1333.

[62]   M. Horberg, B. Tang, W. Towner, et al., “Impact of Tenofovir on Renal Function in HIV-Infected, Antiretroviral-Naive Patients,” Journal Acquired Immune Deficiency Syndrome, Vol. 53, No. 1, 2010, pp. 62-69.

[63]   A. Milinkovic, “Proteinuria as an Early Marker of Tenofovir Renal Toxicity,” 14th IWCADR, 19-21 July 2012, Washington DC, Oral Abstract 005. Antiviral Therapy, Vol. 17, No. 2, 2012, p. 5.

[64]   E. Deti, G. Chene, C. Vandenhende, et al., “Chronic Renal Failure in HIV Infected Patients: Incidence and Risk Factors (ANRS CO3 Aquitaine Cohort, France),” 17th CROI, San Francisco, 2010.

[65]   C. L. Woodward, A. M. Hall, I. G. Williams and S. Madge, “A Copas Tenofovir-Associated Renal and Bone Toxicity,” HIV Medicine, Vol. 10, No. 8, 2009. pp. 482-487.

[66]   C. Fux, M. Simcock, M. Wolbers, et al., “Tenofovir Use Is Associated with a Reduction in Calculated Glomerular Filtration Rates in the Swiss HIV Cohort Study,” Antiviral Therapy,” Vol. 12, No. 8, 2007, pp.1165-1173.

[67]   A. Mocroft, O. Kirk, P. Reiss, et al., Euro SIDA Study Group, “Estimated Glomerular Filtration Rate, Chronic Kidney Disease and Antiretroviral Drug Use in HIV-Positive Patients,” AIDS, Vol. 24, No. 11, 2010, pp. 1667-1678.

[68]   S. Rocha, S. Xerinda, R. Marques, C. Pinero, A. Prisca, M. Tavares, R. Serrao and C. Caldas, “Tenofovir-Associated Nephrotoxicity in the First Year of Therapy,” AIDS 2006 XVI International ADIS Conference, Abstract No. CD B0725.

[69]   W. Manosuthi, W. Prasithsirikul, P. Tantanathip, S. Chimsuntorn, S. Nilkamhangand and S. Sungkanuparph, “Renal Impairment in HIV-1 Infected Patients Receiving Antiretroviral Regimens Including Tenofovir in a Resource-Limited Setting,” Southeast Asian Journal of Tropical Medicine and Public Health, Vol. 42, No. 3, 2011, pp. 643-650.

[70]   E. Overton, D. Nurutdinova, J. Freeman, W. Seyfried and K. Mondy, “Factors Associated with Renal Dysfunction within an Urban HIV-Infected Cohort in the Era of Highly Active Antiretroviral Therapy,” HIV Medicine, Vol. 10, No. 6, 2009, pp. 343-350.

[71]   Y. Cao, Y. Han, J. Xie, Q. Cul, et al., “Impact of a Tenofovir Disoprofumarate plus Ritonavir-Boosted Protease Inbuitor-Based Regimen on Renal Function in HIV-Infected Individuals: A Prospective Muticentre Study,” BMC Infectious Diseases, Vol. 13, 2013, pp. 2-8.

[72]   K. K. Patel, A. K. Patel, R. R. Ranjan, A. A. Patel and J. K. Patel, “Tenofovir-Associated Renal Dysfunction in Clinical Pruchice: An Observational Coliost from Western,” India Journal of Sexual Transmitted Disease and AIDS, Vol. 31, No. 1, 2010, pp. 30-34.

[73]   P. Soler-patient, A. Melendo and C. Noguera-Julian, “Prospective Study of Renal Function in HIV-Infected Pediatric Patients Receiving Tenofovir-Containing HAART Regimens,” AIDS, Vol. 25, No. 2, pp.171-176.

[74]   A. Hall, S. Edwards, M. Lapsley, et al., “Subclinical Tubular Injury in HIV Infected Individuals on Antiretroviral Therapy: A Cross-Sectional Analysis,” American Journal of Kidney Disease, Vol. 54, No. 6, 2009, pp. 1034-1042.

[75]   P. Labarga, P. Barreiro, L. Martin-Carbonero, et al., “Kidney Tubular Abnormalities in the Absence of Impaired Glomerular Function in HIV Patients Treated with Tenofovir,” AIDS. Vol. 23, No. 6, 2009, pp. 689-696.

[76]   F. Post, G. Moyle, H. Stellbrink, et al., “Randomized Comparison of Renal Effects, Efficacy, and Safety with Once-Daily Abacavir/Lamivudine versus Tenofovir/Emtricitabine, Administered with Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: 48-Week Results from the ASSERT Study,” Journal of Acquired Immune Deficiency Syndrome, Vol. 55, No. 1, 2010, pp. 49-57.

[77]   J. L. Campbell, L. Hamzah and A. Frank, “Is TenofovirRelated Renal Toxicity Incompletely Reversible?” Journal of Acquired Immune Deficiency Syndrome, Vol. 56, No. 3, 2011, p. 95.

[78]   P. De Beaudrap, M. B. Diallo, R. Landman, N. F. Guèye, I. Ndiaye, A. Diouf, et al., “Changes in the Renal Function after Tenofovir-Containing Antiretroviral Therapy Initiation in a Senegalese Cohort (ANRS 1215),” AIDS Research and Human Retroviruses, Vol. 26, No. 11, 2010, pp. 1221-1227.

[79]   P. Maggi, D. Bartolozzi, P. Bonfanti, L. Calza, et al., “Renal Complications in HIV Disease; between Present and Future,” AIDS Review, Vol. 14, No. 1, 2012, pp. 37-53.

[80]   B. H. Chi, A. Mwango, M. Giganti, L. B. Mulenga, B. Tambatamba-Chapula, et al., “Early Clinical and Programmatic Outcomes with Tenofovir-Based Antiretroviral Therapy in Zambia,” Journal of Acquired Immune Deficiency Syndrome, Vol. 54, No. 1, 2010, pp. 63-70.

[81]   L. Calza, F. Trapani, S. Tedeschi, B. Piergentili, R. Manfredi, V. Colangeli, et al., “Tenofovir-Induced Renal Toxicity in 324 HIV-Infected, Antiretroviral-Naive Patients,” Scandinavian Journal Infectious Disease, Vol. 43, No. 8, 2011. pp. 656-660.

[82]   A. Sanders, N. Munshi, S. Dhande and A. Dravid, “Tenofovir-Induced Acute Kidney Injury in HIV Infected Patients in Western India: A Resource Limited Setting Perspective,” Journal of the International AIDS Society, Vol. 15, Suppl. 4, 2012, p.1.

[83]   R. Manfredi and L. Calza, “Assessment of Kidney Safety Parameters among HIV-Infected Patients Starting a Tenofovir-Containing Antiretroviral Therapy,” The Open Drug Safety Journal, Vol. 2, 2011, pp. 21-24.

[84]   F. A. Dauchy, S. Lawson-Ayayi, R. de La Faille, F. Bonnet, et al., “Increased Risk of abnormal Proximal Renal Tubular Function with HIV Infection and Antiretroviral Therapy,” Kidney International, Vol. 80, No. 3, 2011, pp. 302-309.

[85]   T. Nishijima, H. Gatanaga, H. Komatsu, K. Tsukada, T. Shimbo, et al., “Renal Function Declines More in Tenofovir than Abacavir-Based Antiretroviral Therapy in LowBody Weight Treatment-Naive Patients with HIV Infection,” PLoS One, Vol. 7, No. 1, 2012, Article ID: 29977.

[86]   A. C. Chua, R. M. Llori, L. Kelvin, P. Cavailler and H. Law, “Renal Safely of Tenofivir Containing Antiretroviral Regimen in a Singapore Cohort,” AIDS Research and therapy, Vol. 9, No. 1, 2012, pp. 2-5.

[87]   S. N. Si-Ahmed, P. Pradat, R. Zoutendijk, M. Buti, V. Mallet, et al., “Efficacy and Tolerance of a Combination of Tenofovir Disoproxil Fumarate plus Emtricitabine in Patients with Chronic Hepatitis B: A European Multicenter Study,” Antiviral Research, Vol. 92, No. 1, 2011, pp. 90-95.

[88]   J. Gallant, M. Parish, J. Keruly and R. Moore, “Changes in Renal Function Associated with Tenofovir Disoproxil Fumarate Treatment, Compared with Nucleoside Reverse-Transcriptase Inhibitor Treatment,” Clinical Infectious Disease, Vol. 40, No. 8, 2005, pp. 1194-1198.

[89]   A. Judd, K. L. Boyda, W. Stohr and D. Dunn, “Effect of Tenofovir Disoproxil Fumarate on Risk of Renal Abnormality in HIV-1-Infected Children on Antiretroviral Therapy: A Nested Case-Control Study,” AIDS, Vol. 24, No. 4, 2010, pp. 525-534.

[90]   L. C. Herlitz, S. Mohan, M. B. Stokes, J. Radhakrishnan, et al., “Tenofovir Nephrotoxicity: Acute Tubular Necrosis with Distinctive Clinical, Pathological, and Mitochondrial Abnormalities,” Kidney International, Vol. 78, 2010, pp. 1171-1177.

[91]   A. Bonjoch, P. Echeverría, N. Perez-Alvarez, J. Puig, C. Estany, et al., “High Rate of Reversibility of Renal Damage in a Cohort of HIV-Infected Patients Receiving Tenofovir-Containing Antiretroviral Therapy,” Antiviral Research, Vol. 96, No. 1, 2012, pp. 65-69.

[92]   D. K, Mark, G. Abby, B. Harry and R. Diane, “Tenofovir-Associated Proteinuria,” AIDS, Vol. 27, No. 3, 2003, pp. 479-481.

[93]   C. W. James, M. C. Steinhaus, S. Szabo and R. M. Dressier, “Tenofovir-Related Nephrotoxicity: Case Report and Review of the Literature,” Pharmacotherapy, Vol. 24, No. 8, 2004, pp. 415-418.

[94]   A. Karras, M. Lafaurie, A. Furco, et al., “Tenofovir-Related Nephrotoxicity in Human Immunodefi Ciency Virus-Infected Patients: Three Cases of Renal Failure, Fanconi Syndrome, and Nephrogenic Diabetes Insipidus,” Clinical Infectious Disease, Vol. 36, No. 8, 2007, pp. 1070-1073.

[95]   S. Murreno, P. Domingo, R. Palacios and J. Santos, “Renal Safety of Tenofovir Disoproxil Fumarate in HIV 1 Treatment Experienced Patients with Adverse Events Related to Prior NRTI Use, Data from a Prospective Cohorts Observation Multicentre Study,” Journal of Acquired Immune Deficiency Syndrome, Vol. 42, No. 3, 2006, pp. 385-386.

[96]   K. McKelvey, “Impairment of Renal Function associated with Tenofovir Therapy,” 19th Annual Conference of the British HIV Association (BHIVA), 16-19 April 2013, Manchester Central Convention Complex.

[97]   K. Wever, M. A. van Agtmael and A. Carr, “Incomplete Reversibility of Tenofovir-Related Renal Toxicity in HIV-Infected Men,” Journal of Acquired Immune Deficiency Syndrome, Vol. 55, No. 1, 2010, pp.78-81.

[98]   A. E. Zimmermann, T. Pizzoferrato, J. Bedford and A. Morris, “Tenofovir-Associated Acute and Chronic Kidney Disease: A Case of Multiple Drug Interactions,” Clinical Infectious Diseases, Vol. 42, No. 2, 2006, pp. 283-290.

[99]   E. J. Heathcote, P. Marcellin, M. Buti, E. Gane, R. A. De Man, Z. Krastev, G. Germanidis, et al., “Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B,” Gastroenterology, Vol. 140, No. 1, 2011, pp. 132-143.

[100]   J. E. Gallant, S. Staszewski , A. L. Pozniak , E. DeJesus, J. M. Suleiman, et al., “Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A 3-Year Randomized Trial,” Journal of American Medical Association, Vol. 292, No. 2, 2004, pp. 191-201.

[101]   B. Young, K. Buchacz, R. Baker, et al., “Renal Function in Tenofovir-Exposed and Tenofovir-Unexposed Patients Receiving Highly Active Antiretroviral Therapy in the HIV Outpatient Study,” Journal of International Association of Physicians AIDS Care (Chic III), Vol. 6, No. 3, 2007, pp.178-187.

[102]   B. Young, K. Buchacz, A. Moorman, K. Wood and J. Brooks, “Renal Function in Patients with Preexisting Renal Disease Receiving Tenofovir-Containing Highly Active Antiretroviral Therapy in the HIV Outpatient Study,” AIDS Patient Care STDS, Vol. 23, No. 8, 2009, pp. 589-592.

[103]   E. P. O’Donnell, K. K. Scarsi, K. M. Darin, L. Gerzenshtein, et al., “Low Incidence of Renal Impairment Observed in Tenofovir-Treated Patients,” Journal of Antimicrobial Chemotherapy, Vol. 66, No. 5, 2011. pp. 1120-1126.

[104]   G. Birkus, M. J. Hitchcock and T. Cihlar. “Assessment of Mitochondrial Toxicity in Human Cells Treated with Tenofovir: Comparison with Other Nucleoside Reverse Transcriptase Inhibitors,” Antimicrobial Agents Chemotherapy, Vol. 46, No. 3, 2002, pp. 716 -723.

[105]   H. Izzedine, J. S. Hulot, D. Vittecoq, et al., “Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in Antiretroviral-Naive HIV-1-Infected Patients: Data from a Double-Blind Randomized Active-Controlled Multicentre Study,” Nephrology Dialysis Transplantation, Vol. 20, No. 4, 2005, pp. 743-746.

[106]   J. Gallant and R. Moore, “Renal Function with Use of a Tenofovir-Containing Initial Antiretroviral Regimen,” AIDS, Vol. 23, No. 15, 2009, pp. 1971-1975.

[107]   E. Martinez, J. A. Arranz, D. Podzamczer, M. Lonca, et al., “A Simplification Trial Switching from Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV1-Infected Patients with Virological Suppression,” Journal of Acquired Immune Deficiency Syndrome, Vol. 51, No. 3, 2009, pp. 290-297.

[108]   C. T. Longenecker, R. Scherzer, P. Bacchetti, C. E. Lewis, C. Grunfeld and M. G. Shlipak, “HIV Viremia and Changes in Kidney Function,” AIDS, Vol. 23, No. 9, 2009, pp. 1089-1096.

[109]   M. Ando, N. Yanagisawa, A. Ajisawa, K. Tsuchiya and K. Nitta, “Kidney Tubular Damage in the Absence of Glomerular Defects in HIV Infected Patients on Highly Active Antiretroviral Therapy,” Nephrology Dialysis Transplantation, Vol. 26, No. 10, 2011, pp. 3224-3229.

[110]   R. T. Schooley, P. Ruanea, R. A. Myers and G. Beall, “Tenofovir DF in Antiretroviral-Experienced Patients: Results from a 48-Week, Randomized, Double-Blind Study,” AIDS, Vol. 16, No. 9, 2002, pp. 1257-1263.

[111]   A. Gayet-Ageron, J. Ananworanich, T. Jupimai, et al., “No Change in Calculated Creatinine Clearance after Tenofovir Initiation among Thai Patients,” Journal of Antimicrobial Chemotherapy, Vol. 59, No. 5, 2007, pp. 1034-1037.

[112]   A. Viganò, G. V. Zuccotti, L. Martelli, V. Giacomet, et al., “Renal Safety of Tenofovir in HIV-Infected Children: a Prospective, 96-Week Longitudinal Study,” Clinical Drug Investigation, Vol. 27, No. 8, 2007, pp. 573-581.

[113]   H. Bygrave, K. Kranzer, K. Hilderbrand, G. Jouquet, E. Goemaere, et al., “Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho,” PLoS ONE, Vol. 6, No. 3, 2011, Article ID: 17609.

[114]   L. Gerard, C. Chazallon, A. Taburet, P. Girard, et al., “Renal Function in Antiretroviral Experience Patients Treated with Tenofovir/Atazanavir,” Antiviral Therapy, Vol. 12, 2007, pp. 31-39.

[115]   K. Squires, A. L. Pozniak, G. Pierone Jr., et al., “Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection: A Randomized Trial,” Annals of Internal Medicine, Vol. 139, No. 5, 2003, pp. 313-320.

[116]   K. Y. Smith, P. Patel, D. Fine, et al., “Randomized, Double-blind, Placebo-Matched, Multicenter Trial of Abacavir/Lamivudine or Tenofovir/Emtricitabine with Lopinavir/Ritonavir for Initial HIV Treatment,” AIDS, Vol. 23, No. 12, 2009, pp. 1547-1556.

[117]   J. R. Arribas, A. L. Pozniak, J. E. Gallant, et al. “Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared with Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis,” Journal of Acquired Immune Deficiency Syndrome, Vol. 47, No. 1, 2008, pp. 74-78.